PTO/SB/08A	/10 <u>-9</u> 8\

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bubstitute for form 1449A/PTO

IFORMATION DISCLOSURE MENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known	
Application Number	09/898,616	
Filing Date	July 2, 2001	
First Named Inventor	Pilon et al.	
Group Art Unit	1647	
Examiner Name	Hunnicatt, Rachel Kapust	
An Book of Months	116142/00170	

			U.S. PATENT DOCUM	MENTS	
Examiner thitials *	Cite No.1	Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear
M	AA	5,696,092	Patiemo et al.	12/09/97	
M	AB	5,266,562	Mukherjee et al.	11/30/93	
6					
,					

				FOREIGN PA	ATENT DOCUMENT	'S		
	Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where			
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T ₆
Rel	BA	1	WO 98/4	0657		12/19/96		I
III	BB	 	WO 96/0	9831		04/04/96		
14	BC	 	EP 0617	7965		10/05/94		I
M	BD	 	WO 88/0			11/17/88		
								<u> </u>

Examiner Signature	PL.	Date Considered	8/28/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

PTO/SB/08A (10-98)

Approved for use through 10/31/99, OMB 0851-0031=

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/898,616 INFORMATION DISCLOSURE July 2, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Pilon et al. Group Art Unit 1647 (use as many sheets as necessary) Hunnicatt, Rachel Kapust **Examiner Name** 116142/00170

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	/
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1.	ABMAN et al., "Pathophysiology and Treatment of Bronchopulmonary Dysplasia: Current Issues." Pediatric Clinics of North America, Vol. 41 No. 2, pp. 277-315 (1994).	
	2.	AKIYAMA et al., "Fibronectin and Integrins in Invasion" Cancer and Metastasis Reviews. Vol. 14, pp. 173-189 (1995).	
	3.	ANDERSSON et al., "Heterologous Expression of Human Uteroglobin/Polychlorinated Biphenyl-binding Protein." J. Biol. Chem., Vol. 269 pp.19081-19087 (1994).	
	4.	AOKI et al., "Isolation of Human Uteroglobin from Blood Filtrate." Mol. Hum. Reprod., Vol. 2, pp. 489-497 (1996).	
	5.	ASSMANN et al., "Familial Glomerulonephritis Characterized by Massive" Am. J. Kid. Dis., Vol 25, pp. 781-791 (1995).	
	6.	Badcock, N.R. et al., "False-Positive EMIT RTMst.TM. Ethanol Screen with Post-Mortem Infant Plasma", Clinical Chemistry, vol. 38, No. 3: 434-435 (1992).	
	7.	BARNES et al., "Structural Basis for Calcium" JMB, Vol. 256, pp. 392-404 (1996).	
	8.	BARTON et al., "Amino Acid Sequence Analysis of the" Eur. J. Biochem., Vol. 198, pp.749-760 (1991).	
	9.	BEIER, H.M., "Uteroglobin: A Hormone-dependent Endometrial Protein Involved in blastocyst Development," Biochem. Biophys. Acta, Vol. 160, pp. 289-291 (1968).	
	10.	BPRENBAUM, F., "Phospholipase A2 inhibitors: a challenge for the future." Ref. Rhum. Engl. Ed., Vol. 62. pp 409-14 (1995).	
	11.	BERNARD, et al., "Serum Clara Cell Protein: An Indicator," Env. Res., Vol. 66, pp. 96-104 (1994).	
	12.	BERNARD et al., "Clara Cell Protein in Serum and Bronchoalveolar Lavage," Eur. Respir. J. Vol. 5, pp. 1231-1238 (1992a).	

Examiner Signature	Phe.	Date Considered	8/28/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

L	Complete if Known
Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

	.,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
-	13.	BERNARD et al., "Human Urinary Protein 1: Evidence for Identity with the Clara Cell Protein and Occurrence in Respiratory Tract and Urogenital Secretions," Clin. Chim. Act., Vol. 207, pp. 239-249 (1992b).	
	14.	BERNARD et al., "Selective Increase in the Urinary Execretion of Protein I (Clara Cell protein) and other low molecular weight proteins during normal pregnancy," Scand. J. Clin. Lab. Invest. Vol. 52, pp. 871-878 (1992c).	
	15.	BERNARD et al., "Protein 1 is a Secretroy Protein for the Respiratory and Urogenital Tracts Identical to the Clara Cell Protein," Clin. Chem. Vol. 39, pp. 434-435 (1992d).	
	18.	BERNARD et al., "Determination by Latex Immunoassay of Protein 1 in Normal and Pathological Urine," Clin. Chem. Acta., Vol 201, pp. 231-246 (1991).	
	17.	BERNARD et al., "Urine Protein 1: a Sex-Dependent Marker of Tubular or Glomerular Dysfunction," Clin. Chem. Vol. 35, pp. 2141-2142 (1989).	<u> </u>
· · · · · ·	18.		
	19.	CAMUSSI et al., "Anti-inflammatory peptides (artiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation, and chemotaxis, and infradermal inflammatory reactions, "J. Exp. Med., Vol. 171, pp. 913-927 (1995a).	
	20.	CAMUSSI et al., "Antiflammins Inhibit Synthesis of Platelet-Activating," Biochem, Mol. Biol. and Physiol. of Phospholipase A2 and its Regulatory Factors, pp. 161-172 (1990).	
	21.	CHAN et al., "Antiflampuns: Inhibit of Endotoxin-induced Uveitis in Lewis Rats," In Ocular Immunology Today (Usui, Ohno, and Aoki. Eds.). Elsevior Science Publishers, Amsterdam, pp. 467-470 (1990).	
	22.	CHAN et al., Effects of Antiflammins on Endotoxin-Induced Uveitis in Rats, "Arch. Opthamol., Vol. 109, pp. 278-291 (1991).	
	23.	CHIESA M et al. "Significant Increase in Immunoregulatory Protein Blastokinin/Uteroglobin in Jen/Fibronectin Complexes in Sera of Patients with IgA Nephropathy" Nephrology Dialysis Transplantation, Vol. 15, Mo. 9 p. A39 (2000).	
	24.	Daly, H. et al. "Bleomycin Induces Strain-Dependent Alterations in the Pattern of Epithelial Cell-Specific Marker Expression in Mouse Lung", Toxicology and Applied Pharmacology, vol. 142: 303-310 (1993).	
$\overline{/}$	25.	DENNIS et al., "Multiple forms of phospholipase A2 in macrophages capable of arachidonic acid release for cicosanoid biosynthesis," Adv. Prostaglandin Thromboxane Leukot Res., Vol. 23, pp. 75-80 (1995a).	

Examiner Signature	BL	Date Considered	8/28/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached:

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Complete if Known		
WEADALTION DIOCI COURT	Application Number	09/898,616	
INFORMATION DISCLOSURE	Filing Date	July 2, 2001	
STATEMENT BY APPLICANT	First Named Inventor	Pilon et al.	
	Group Art Unit	1647	
(use as many sheets as necessary)	Examiner Name	Hunnicatt, Rachel Kapust	
Sheet 4 of 8	Attorney Docket Number	116142/00170	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	_
	26.	DENNIS E.A., "Potential phopholipase A2s involved in inflammatory diseases," Agents Actions Suppl., Vol. 46, pp 35-39 (1995b).	,
	27.	Dhanireddy, R. et al., "Uteroglobin-Like Protein Levels in Premature Infants on Long Term Venilator Support", Pediatric Research vol. 33, No. 323A, (1993).	
	28.	Dhanireddy, R. et al., "Uteroglobin-Like Protein in Premature Infants: Effect of Gestational Age", Pediatric Research, vol. 23, No. 463A, Abstract No. 1567 (1988).	
	29.	Dhanireddy et al, "Uteroglobin-like Protein in Premature Infants: Effect of Gestational Age," Ped. Res., vol. 23, pp. 463A (1988b).	
	30.	Dhanireddy, R. et al., "Detection of a Rabbit Uteroglobin-Like Protein In Human Neonatal Tracheobronchial Washings", Biochemical and Biophysical Research Communications, vol. 152, No. 3: 1447-1554 (1988).	
	31.	DHANIREDDY et al., "Ontogeny of Uteroglobin in Relation to, " Pd. Res., 299A.*	
	32.	DIERYNCK et al., "The human Clara cell protein: biochemical and biological," Mult. Schler., Vol. 1, No. 6, pp. 385-387 (1996).	
	33.	Dierynck, I. et al., "Potent Inhibition of Both Human Interferon-gamma. Production and Biologic Activity By the Clara Cell Protein CC-16", American Journal of Respiratory Cell Molecular Biology, vol. 12: 205-210 (1995).	
	34.	EDELSON et al., "Acute Lung Injury Induced by Phospholipase A2: Structural and Functional Changes," Am Rev. Respir. Dis., Vol. 143, pp 1102-1109 (1991).	
	35.	Facchiano, A. et al., "Inhibition of Pancreatic Phospholipase A.sub.2 Activity By Uteroglobin and Antiflammin Peptides: Possible Mechanism of Action" Life Sciences, vol. 48: 453-646 (1991).	
	38.	Federal Register, published Aug. 16, 1994.	
	37.	Fung, T-C., et al., "Surfactant: Coming of Age for the Treatment of RDA", The Journal of Respiratory Diseases, vol. 13, No. 4: 609-617 (1992).	
: - · · · · · · · · · · · · · · · ·	38.	Gerdes, J., et al., "Tracheal Lavage and Plasma Fibronectin: Relationship to Respiratory Distress Syndrome and Development of Bronchopulmonary Dysplasia", The Journal of Pediatrics, pp. 601-606 (1986).	
	39.	Glaser, K.B., "Regulation of Phospholipase A.sub.2 Enzymes: Selected Inhibitors and Their Pharmacological Potential", in Advances In Pharmacology, vol. 32 Academic Press Incorporated, pp. 31-66 (1995).	
	40.	Grorieck, P. et al. "Association of Pulmonary Inflammation and Increased Microvascular Permeability During the Development of Bronchopulmonary Dysplasia: A Sequential Analysis of Inflammatory Mediators in Respiratory Fluids of High-Risk Preterm Neonates", Pediatrics, vol. 93 No. 5: 712-718 (1994).	
	41.	GUY et al., "Surfactant-producing Rabbit Pulmonary Alvcolar Type II Cells," BBRC, Vol. 189, pp. 662-669 (1992).	
	42.	Hard, P. et al., "Solution Structure Of A Mammalian PCB-Binding Protein In A Complex With a PCB", Nature Structural Biology, vol. 2, No. 11: 983-989 (1995).	
1	43.	lalenti, A., et al. "Anti-inflammatory Effects of Vasocortin and Nonapeptide Fragments of Uteroglobin and Lipocortin 1 (Antiflammins)", Agents and Actions, vol. 29: 1-2 (1990).	

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/898,616

Filling Date July 2, 2001

First Named Inventor Pilon et al.

Group Art Unit 1647

Examiner Name Hunnicatt, Rachel Kapust

(use as many sheets as necessary)

(use as m	any sheets as necessary)		Examiner Name Hunnicatt, Rachel Kapust						
Sheet 5		of	8	Attorney Docket Number	116142/00170					
	144. Itoh et al. "Protein 1: Its Purification and Application in Clinical Medicine" J. Clin. Lab. Anal. 7: 394-400 (1993).									
	45.	Jackson, P. et al., "Purification and Partial Amino Acid Sequence of Human Urine Protein 1", Journal of Chromatograph, 452: 359-367 (1988).								
	46.			Cell Protein, An Endogenous Phospholipase A.sub.2 Inhibitor, In y Journal, vol. 8: 1647-1653 (1995).						
	47.	KIKUKAWA Temporal Rel	KIKUKAWA, et al., "Partial Characterization of a Uteroglobin-Like Protein in the Human Uterus and Its Temporal Relationship to Prostaglandin Levels in This Organ," J. Clin. Endo & Met. 67(2): 315-221.							
	48.	Krishnan, R., "'Blastokinin': Inducer and Regulator of Blastocyst Development in the Rabbit Uterus", Science, vol. 158:490-492 (1967).								
	49.	Kundu, T., et al., "Recombinant Human Uteroglobin Suppresses Cellular Invasiveness Via a Novel Class of High-Affinity Cell Surface Binding Site" Proceedings of the National Academy of Sciences, USA, vol. 93: 2915-2919 (1996).								
	50.	Workers), che	Lesur, O. Clara Cell Protein (CC-16) In Ensurfactint-Associated Protein A (SP-A) an Absestos-Exposed Workers), chest, vol. 109, No. 2: 467-474 (1996).							
	51.	Lesur, O. et a Fibroblast Mi (1995).	I. "Clara Cell Protein (CC- igration In vitro" American	16) Induces a Phospholipase A.su Journal of Respiratory Critical Co	6.2 -Mediated in Addition of are Medicine vol. 152: 290-297					
	52.	Levin, S., et a (1986).	Levin, S., et al., "Uteroglobin Inhibits Phospholipase A.sub.2 Activity", Life Sciences, vol. 38: 1813-1819							
	53.	LEYTON et 54 pp 3696-3		Iteroglobin Inhibits the In Vitro Ir	nvasiveness, " Cancer Res., Vol.					
	54.	Lindhal et al. bronchoalved	, "Demonstration of differe lar lavage fluids", Electrop	nt forms of lipocortin-1 and Clara horesis 20: 881-890 (1999).	a cell protein-16 in human nasal and					
	55.			Fragments of Uteroglobin and Lip armacology vol. 264: 379-384 (19	occortin I on Oedema and Mast Cell 1994).					
	56.			Virinary Factor from Women in ol. 4, No. 4? 428-434 (1998).	Early Preganancy of HIV I, SID and					
	57.		L et al. "Inhibition of Throi y, vol. 36, No. 5-741-746 (nbin-Induced Platelet Aggregation 1987).	n By Uteroglobin" Biochemical					
	58.		k. et al., "Crosslinking of U mmunications, vol. 121, No	teroglobin By Transglutaminase" o. 1: 400-407 (1984).	Biochemical and Biophysical					
	59.	Mantile, G., o Biological Cl	et al. "Human Clara Cell 10 nepristry, vol. 268, No. 27:	0-kDa Protein is the Counterpart o 20343-20351 (1993).	f Rabbit Uteroglobin" Journal of					
	60.	Protein", PR	OTEINS: Structure, Function	d Characterization of the Recombion and Genetics, 20: 191-196 (199	94).					
	61.	Miele L. et a Interchain Di No. 11: 6427	sulfide Bridges, in its natur	xpression of Uteroglobin, A Dimeral quaternary Structure* Journal of	eric Eukaryotic Protein with Two of Biological Chemistry, vol. 265,					
	67/	Miele, L., et Phospholipas	al., "Uteroglobin: Structure e A.sub.2 Inhibitor" Endoc	, Molecular Biology, and New Perine Reviews, vol. 8, No. 4: 474-4	rspectives on Its Function as a 490 (1987)					
	63.	Miele, L., et Endocrinolog	al. "Uteroglobin and Uterogy y Investigations, vol. 17: 6	globin-Like Proteins: The Uterogl 179-692 (1994).	obin Family of Proteins" Journal of					
	64.	Miele, L. et a Uteroglobin	ıl. "Novel Anti-İnflammato and Lipocortin I", Nature, v	ry Peptides From the Region of H vol. 335, No. 6192: 726-730 (1988	ligher Similarity Between 3).					
1	65.	Mihal, K., "C pp. 1-3 (1991		oteins with different functions," A	um. J. Respir. Cell. Mol. Biol., vol. 5,					

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/898,616

Filing Date July 2, 2001

First Named Inventor Pilon et al.

Group Art Unit 1647

Examiner Name Hunnicatt, Rachel Kapust

(use as	many sheets as necessary)	Examiner Name	Hunnicatt, Rachel Kapust						
Sheet 6	of 8	Attorney Docket Number	116142/00170						
66	MUKHERJEE et al., "Modulation of Cellular Response to Antigens by Uteroglobin and Transglutaminase" Adv. Exp. Med. Biol., 231:135-152 (1988).								
67	MUKERJEE eta I., "Regulation of Extracellular Phospholipase A2 Activity: Implication for Inflammatory Diseases" DNA and Cell Biology, Vol. 11, No. 3 pp. 233-243 (1992-04).								
68	MUKERJEE A B et al. "Could the Gene Coding for Human Uteroglobin (Clara Cell 10kDa Protein) be a candiate gene for Atopy?" American Journal of Human Genetics Vol. 55 No. 3 pA 197 (1994).								
69	Mukherjee, A. et al., "Phospholipase A.sub.2 Enzymes: Regulation and Physiological Role", Biochamical Pharmacology, vol. 48, No. 1: 1-10 (1994).								
70	Nomori, H. "Protein I (Clara Cell) Scrum Levels in Healthy Subjects in Patience With Bacterial Pneumonia" American Journal of Respiratory Critial Care Medicine, vol. 152: 746-750 (1995).								
71	Nomori, H., et al. "Protein 1 and Clara Cell 10-kDa Protein Distribution in Normal and Neoplastic Tissued with Emphasis on the Respiratory System", Virchows Archives, vol. 424: 517-523 (1994).								
72	Fossil Liposomes" EFEBS Letters vol. 3	Nord, M. et al., "Calcium-Dependent Binding of Uteroglobin (PCB-BP/CCSP) Two Negatively Charged Fossil Liposomes" EFEBS Letters vol. 374: 403-406 (1995).							
73	 Chromatography: Evidence for the Ident 	Okutani, R. et al., "Simple and High-Yield Purification of Urine Protein Using Immunoaffinity Chromatography: Evidence for the Identity of Urine Protein 1 and Human Clara Cell 10-Kilodalton Protein", Journal of Chromatography, vol. 577: 25-35 (1992). Olson et al. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell Apr. 1996 5;85(1):1-4.							
74									
75	Ovarian Menstrual Cycle," DNA and Ce	II Biology, 13(5):495-503 (1994)							
76	PERI A et al., "Uteroglobin Gene Expreso. Relationship between Uteroglobin and E Investigation, Vol. 96, No. 1 pp 343-353	icosanoid Levels in the Developing	nout gestation and in Fetal Lung: ng Fetal Lung." Journal of Clinical						
77	Perri, A. et al., "Tissue-Specific Expression of the Gene Coating For Human Clara Cell 10-kD Protein, a Phospholipase A.sub.2 -Inhibitory Protein, Journal of Clinical Investigations, vol. 92: 2099-2109 (1993).								
78	Peter, W., "Recombinant Rabbit Uterogl Binds Progesterone", Protein Engineerin		E. coli Forms Stable Dimers and						
. 78	Peteres et al, "Clinical determinants of al Respir. Dis., vol. 139, pp. 1165-1168 (19	bnormalities in pulmonary function 289).	ons in survivors of ," Am. Rev.						
80	Piomelli, D., "Arachidoric Acid in Cell Signaling", Current Opinion in Cell Biology, 5: 274-180 (1993).								
81	 Comparison of the 5'-Flanking Region V Research Communications, vol. 197, No 	crization of the Mouse Clara Cell Specific 10 kDa Protein Gene on With the Human Rat and Rabbit Gene", Biochemical and Biophysical No. 1: 163-171 (1993).							
82	RENNARD et al., "Production of Fibron Recruitment of Fibroblasts to Sites of Ti 78(11): 7147-7151 (1988).								
83	3. Robinson, D., "Macromolecular Transpor Transport System", Molecular and Cellu	ort in Rabbit Blastocysts: Evidence lar Endocrinology, 63: 227-237 (e for a Specific Uteroglobin 1989).						
84	Ruoslahti et al, "Fibronectin and Its Reco	eptors," Ann. Rev. Biochem., vol.	57, pp. 374-413 (1988).						
85	5. Shijubo, N. et al. "Serum and BAL Clare Cells Are Decreased In Smokers", Europ	a Cell 10 kDa Protein (CC10) Levoean Respiratory Journal, vol. 10:	rels and CC10-Positive Bronchiolar 1108-1114 (1997).						
86									
87	Singh, G. et al. "Mouse Clara Cell 10-kl for the Variation of Progesterone Bindin 19: 67-75 (1993).	Da (CC10) Protein: cDNA Nucleo g of CC10 from Different Species	tide Sequence and Molecular Basis ", Experimental Lung Research vol.						

Substitute for form 1449A/PTO Complete if Known 09/898,616 Application Number INFORMATION DISCLOSURE July 2, 2001 Filino Date STATEMENT BY APPLICANT Pilon et al. First Named Inventor 1647 Group Art Unit (use as many sheets as necessary) Hunnicatt, Rachel Kapust **Examiner Name** 116142/00170 of Attorney Docket Number Sheet Singh et al, "Identification, Cellular Localization, Isolation, and Characterization of Human Clara Cell-88. Specific 10 KD Protein, J. Hist. Cyt., vol. 36, pp. 73-80 (1988b). Singh, G. et al., "Clara Cell 10 kDa protein (CC10): Comparison of Structure and Function to Uteroglobin", 89. Biochimica et Biophysica Acta, 1039:348-355 (1990). Singh, G., et al., "Isolation and Amino Acid Composition of the Isotypes of a Rat Clara Cell Specific Protein", 90 Experimental Lung Research, 13:299-309 (1987). Stenmark et al, "Potential role of cicosanoids and platelet-activating factor in the pathophysiology of BPD," Am. Rev. Resp. Dis., vol. 136, pp. 770-772 (1987). Stripp et al, "Clara cell secretory protein: a determinant of PCB bioaccumulation in mampfals," Am. J. 92. Physiol., 271 (Lung Cell Mol. Physiol. 15), pp. L656-L664 (1996). Stripp et al, "Plasticity of airway cell proliferation and gene expression after acute naphthalene injury," Am. J. 93. Physiol., vol. 269, pp. L791-L799 (1995) Stripp, B. et al. "Structure and Regulation of the Murine Clara Cell Secretory," rotein Gene", Genomics vol. 94 20: 27-35 (1994). Stripp, B. et al., "cis-Acting Elements That Confer Lung Epithelial Cell/Expression of the CC.sub.10 Gene", 95. Journal of Biological Chemistry, vol. 267, No. 21: 14703-14712 (1992). Tykka et al. A randomized double-blind study using CaNa2EDT A, a phospholipase A2 inhibitor, in the 96 management of human acute pancreatitis. Scan. J. Gastroenterology, (Jan. 1985) 20 (1) 5-12. Tykka et al. Phospholipase A2 inhibitors and their possible clinical use in the treatment of acute pancreatitis. Scand J Gastroenterol 1980;15(5):519-28, Abstract only, Umland et al, "Twixt form and function," Nat. Strugt. Biol., vol. 2, pp. 919-922 (1995). 98. Umland et al, "Structure of human Clara cell phopholipid-binding protein-ligand complex at 1.9 A resolution," Nature Struct. Biol., vol. 1, pp. 538-545 (1994). VADAS et al, "Potential therapeutic efficacy of inhibitors of...," Agents Actions, Vol. 19, pp. 194-202 (1986). 100 Van Bisbergen et al, "Synthetic pertide from lipocortin 1 has no phospholipase inhibitory activity," FEBS 101 Lett., vol. 247, pp. 293-297 (1939). VAN VYVE et al., "Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects", J. of Allergy and Clin. Immun., vol. 95 no. 1 pp. 60-68 (1995) Van Winkle, L. et al. Repair of Naphthalene-Injured Microdissected Airways In vitro" American Journal of 103 Respiratory Cell and Molecular Biology, vol. 15: 1-8 (1996). Vasanthakumar, G., "Inhibition of Phagocyte Chemotaxis By Uteroglobin, An Inhibitor of Blastocyst Rejection", Brochemical Pharmacology, vol. 37, No. 3: 389-394 (1988). Volovitz, B. et al., "Relationship Between Leukotriene C4 and a Uteroglobin-Like Protein in Nasal and 105 Traches bronchial Mucosa of Children" Int. Arch. Allergy Applied Immunology, vol. 86: 420-425 (1988). Vostal, J. et al., "Novel Peptides Derived From a Region of Local Homology Between Uteroglobin and Lipocortin-1 Inhibit Platelet Aggregation and Secretion", Biochemical and Biophysical Research 106 Communications, vol. 165, No. 1: 27-36 (1989). Wu, C., et al. "Integrin Activation and Cytoskeletal Interaction Are Essential for the Assembly of a

Wuenschell et al, "Embryonic mouse lung epithelial progenitor cells . . . ," J. Histochem Cytochem, vol. 44,

Wuenschell, C. et al., "Embryonic Mouse Lung Epithelial Progenitor Cells Co-Express Immunohistochemical Markers of Diverse Mature Cell Lineages", The Journal of Histochemistry and Cytochemistry, vol. 44, No. 2:

Zhang, Q. et al., "Cross-linking of the NH.sub.2 -Terminal Region of Fibronectin to Molecules of Large Apparent Molecular Mass", The Journal of Biological Chemistry vol. 271, No. 52: 33284-33292 (1996).

Fibronectin Matrix", Cell, vol. 83: 715-724 (1995).

pp. 113-123 (1996).

e ,

+

Substitute for form 1449A/PTO						Complete if Known			
INFORMATION DISCLOSURE					Application Number	09/898,616			
					Filing Date	July 2, 2001			
STATEMENT BY APPLICANT (use as many sheets as necessary)				PPLICANT	First Named Inventor	Pilon et al.			
					Group Art Unit	1647			
				necessary)	Examiner Name	Hunnicatt, Rachel Kapust			
Sheet	8	8		8	Attorney Docket Number	116142/00170			
	111.			Modulation of Cell Surfi 447-1459 (1994).	tion of Cell Surface Fibronectin Asembly Sites by Lysophosphatidic Acid," J. Cell Biol., 59 (1994). It of Dexamethasone Therapy on Pibronectin and Albumin Levels in Lung Secretions of pulmonary Dysplasian J. Pediat. 121: 597-607 (1992). Levele Fibronectin-Deposit Renal Glomerular Disease in Mice Lacking Uteroglobin." 5. 5317 pp 1408-1412 (1997).				
	112.	WATTS Infants v	Set al. with B	, "Effect of Dexamethas ronchopulmonary Dysp					
	113.								
	114.		ANG ZH et al., "Human uteroglobin gene: Structure, subchromosomal localization and polymorphism",						

Customer No. 31013

OCT 1 5 2004 2

Attorney Docket No. 116142/170 Sheet 1 of 1

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 116142/170		SERIAL NO. 09/898,616			
		NCES CITED BY							
((Jse seve	eral sheets if necess	ary)	APPLICANTS Pilon et al.	<u> </u>	<u> </u>			
				FILING DATE	GROUP ART UNIT				
<u>-</u>			TIC DAT	July 2, 2001		1647	 		
		Τ	U.S. PA1	ENT DOCUMENTS		1	FILING		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	DATE IF APPROPRI	IATE	
M	AA	4,691,009	09/01/87	Palmer et al.	T				
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	ΑI								
	AJ		<u> </u>				<u></u>		
		· · · · · · · · · · · · · · · · · · ·		PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
		<u> </u>				ļ	YES	NO	
	BA						<u>-</u>	 	
	BB	ļ <u>.</u>				 		 	
	BC	 	_					+	
	BD	OWINED BY	DY TO A TYONG (Total disease Tide D	-ta Daminant I	Dance Eta \		<u> </u>	
	104	OTHER PU	BLICATIONS (I	ncluding Author, Title, D teroglobins it the rabbit.	Two similar n	otoing with	differential		
M	CA	hormonal regulat	ion", Biochim Bio	ophys Act. 1978, Vol. 544	, No. 3, pp. 57	8-592.			
M	СВ	Protein", J. Biol.	Chem., 22 July 19	opression of Human Utero 1994, Vol. 269, No. 29, pp.	19081-19087			ng 	
BL	CC	Mourot et al., "Comparative Evaluation of Ultrafiltration Membranes for Purification of Synthetic Peptides", Separation Science and Technology, 1989, Vol. 24, No. 5 & 6, pp. 353-367.							
Pel	CD	Shin et al., "Enha	Shin et al., "Enhanced Production of Human Mini-Proinsulin in Fed-Batch Cultures at High Cell Density of Escherichia coli BL21 (DE3)[pET-3aT2M2]", Biotechnol. Prog., 1997, Vol. 113, pp. 249-257.						
M	CE								
., -	CE	Modeling of Liga	ind Binding , Ain	1. N 1 . Acad. Sci. 2000, V	01. 923, pp. 11	3-127.			
	CF CG								
	CH	 						, -	
······································	CI	 							
	CI								
· · · · · · · · · · · · · · · · · · ·	CK								
	CL								
	CN	<u> </u>							
EXAMINER	<u></u>	BL		DATE CONSIDER	DATE CONSIDERED 8/29/05				
* EXAMINE				citation is in conformance w			rough citation	if not in	